Description
Celoda (Capecitabine) Coated Tablets 150 mg. №60
Ingredients
Each coated tablet contains 150 mg of capecitabine.
Mechanism of Action
Celoda (capecitabine) is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body. 5-FU is an antimetabolite that interferes with DNA synthesis and cell division, ultimately leading to cell death. This mechanism of action makes Celoda effective in inhibiting the growth of cancer cells.
Pharmacological Properties
Celoda exhibits cytotoxic effects by disrupting DNA synthesis through the conversion to 5-FU, thereby impeding cancer cell proliferation. It is well-absorbed orally and undergoes conversion to its active form in tissues with high levels of thymidine phosphorylase, commonly found in tumors.
Indications for Use
Celoda is indicated for the treatment of various types of cancer, including breast, colorectal, and gastric cancers. It is used either alone or in combination with other chemotherapy medications.
Contraindications
Celoda is contraindicated in patients with known hypersensitivity to capecitabine or any of the excipients in the formulation. It should not be used in patients with severe renal impairment or dihydropyrimidine dehydrogenase (DPD) deficiency.
Side Effects
Common side effects of Celoda may include hand-foot syndrome, diarrhea, nausea, and fatigue. Patients should be monitored regularly for blood counts and liver function due to potential adverse effects.
Usage Instructions
Celoda tablets should be taken with water within 30 minutes after a meal. The dosage schedule may vary based on the treatment regimen. It is important to swallow the tablets whole and not crush or chew them.
Benefits Compared to Analogues
Celoda offers the advantage of oral administration with comparable efficacy to traditional intravenous 5-FU regimens. Its prodrug nature allows for targeted conversion to the active form, reducing systemic toxicity and improving patient convenience.
Suitable Patient Groups
Celoda is suitable for adult patients with various cancer types. Dosing adjustments may be necessary for elderly individuals or those with specific comorbidities. It is not recommended for use in pediatric populations.
Storage and Shelf Life
Celoda should be stored at room temperature away from moisture and heat. The shelf life of the product is as indicated on the packaging.
Packaging Description
Celoda is available in blister packs containing 60 coated tablets of 150 mg strength. The packaging should be kept intact until the tablets are ready for use to prevent exposure to external elements.
Clinical Evidence and Proven Effectiveness
Clinical trials have demonstrated the efficacy of Celoda in various cancer types, showing improvements in progression-free survival and overall survival rates. Additionally, studies have highlighted the favorable safety profile of Celoda compared to traditional intravenous 5-FU regimens.
